Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the condition when steroids or surgery fail, by targeting the inflammatory cascade that drives their growth.
Nasal polyps are benign growths on the inside of the nose that resemble bunches of grapes. Although noncancerous, they can block the nasal passages, causing difficulty breathing and sinus infections, and interfere with the sense of smell.
“They’re a little like weeds,” said Amrita Ray, DO, otolaryngologist at Henry Ford Health in Detroit. “Even if we cut them out, they try to come back.” Read more in Medscape.